VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on May 24, 2018 (the "Meeting").

The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 40,086,159 Common Shares, representing 62.42% of VBI's issued and outstanding Common Shares as of the record date for the Meeting.

The voting results with respect to each of the following seven director nominees, as described in the Company's proxy statement dated April 10, 2018 (the "Proxy Statement"), all of whom previously served as directors of the Company, were as follows:

Nominee Votes For % Votes Withheld %
Jeff R. Baxter 24,985,860 98.59% 356,802 1.41%
Steven Gillis 24,418,014 96.35% 924,648 3.65%
Michel De Wilde 24,992,910 98.62% 349,752 1.38%
Adam Logal 24,995,180 98.63% 347,482 1.37%
Tomer Kariv 25,030,892 98.77% 311,770 1.23%
Scott Requadt 24,999,397 98.65% 343,265 1.35%
Steven D. Rubin 19,931,897 78.65% 5,410,765 21.35%

Each of the other matters put forward before the Shareholders for consideration and approval at the Meeting, as described in the Proxy Statement, were duly approved by the requisite number of votes. The Shareholders voted in favor of setting the number of directors at seven, appointing EisnerAmper LLP as VBI's independent registered public accounting firm for the ensuing year and authorizing the audit committee of VBI's board of directors to fix its remuneration.

Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company's report of voting results filed on the Company's profile on SEDAR at www.sedar.com.